Chiron Capital Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Chiron Capital Management’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$3K	–	345
2020 Q3	$3K	Buy	+50	New	+$3.27K	﹤0.01%	423

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

AWMS

Advocacy Wealth Management Services Atlanta, Georgia $2.75B AUM 19.24% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Chiron Capital Management's PJP Position: Q4 2020 in Review

Chiron Capital Management sold out of Invesco Pharmaceuticals ETF (PJP) in Q4 2020, closing a stake of 50 shares — an estimated $3K sold.

Chiron Capital Management first reported a position in PJP in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 87 funds tracked by Wall St. Rank hold PJP as of Q4 2020.

Chiron Capital Management reported no remaining Invesco Pharmaceuticals ETF position as of Q4 2020 after selling out during the quarter.
Chiron Capital Management sold 50 Invesco Pharmaceuticals ETF shares in Q4 2020, an estimated $3K.
Chiron Capital Management first reported a position in Invesco Pharmaceuticals ETF in Q3 2020 and held it in 1 quarter.
Chiron Capital Management's Invesco Pharmaceuticals ETF position peaked at $3K in Q3 2020.
87 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.